castrate resistant prostate cancer

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT.  However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

By |2017-10-19T10:48:30-04:00March 21st, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Cabazitaxel, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments
Read More

Analyzing Time to Developing Castration-Resistant Prostate Cancer and Overall Survival after Initiating Androgen Deprivation Therapy (ADT)

There are different methods of performing ADT; these methods include continuous or intermittent as well as differences in the actual blockade itself. Understanding the superior schedule as well as the superior combination of drugs can both delay the onset to castrate resistance as well as provide for a longer overall survival (OS). In a research [...]

By |2017-10-19T10:48:31-04:00March 11th, 2014|Advanced Prostate Cancer, CAB, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|4 Comments
Read More

Castrate Resistant Prostate Cancer- What To Do Next?

Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]

By |2020-02-04T10:11:58-05:00March 4th, 2014|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, enzalutamide, General Information, Prostvac, Provenge, Understanding APC, Xtandi, Zytiga|1 Comment
Read More

Testosterone Therapy for Prostate Cancer: Feeling Better while Defeating Cancer

Although there are now many new treatments for advanced prostate cancer, hormone therapy (ADT) has remained the standard of care for the last 70 years. While hormone therapy can provide pain relief, it is never curative. Long-term hormone therapy produces decreased quality of life. Men treated with hormone therapy have weight gain, experience impotence, decreased [...]

By |2017-10-19T10:49:35-04:00August 5th, 2013|Advanced Prostate Cancer, Advocacy, Drugs & Treatments, Hormone Therapy, How We Live, Prostate Ponderings, Research, Start A Cure, Uncategorized, Understanding APC|0 Comments
Read More

The AUA Issues Specific Guidelines for the Treatment of Men with Castrate Resistant Prostate Cancer

There was a lot of interesting and important presentations at the recent American Urological Association meeting, however the one item that will have the most impact on men with advanced prostate cancer is the new guidelines that were proposed for the treatment of men with castrate resistant prostate cancer. The guidelines were organized by creating [...]

By |2020-02-04T10:48:43-05:00May 8th, 2013|2nd line hormone therapy, abiraterone acetate, Advanced Prostate Cancer, AUA, Chemo Therapy, Drugs & Treatments, enzalutamide, Enzalutamide (MDV-3100), General Information, How We Live, Prostate Ponderings, Provenge, Uncategorized, Understanding APC, vaccines|0 Comments
Read More

Why Prostate Cancer that is Hormone Resistant Still Responds to Hormone Manipulation

I don’t understand why if I have hormone resistant advanced prostate cancer why the new drugs, Zytiga and Xtandi work. These drugs are still hormone therapies, is my prostate cancer hormone resistant? I recently received an email asking me this question and I thought it might be a question many people have, so I am [...]

By |2017-10-19T10:50:00-04:00April 19th, 2013|2nd line hormone therapy, abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, Enzalutamide (MDV-3100), Hormone Therapy, MDV3100, Uncategorized, Understanding APC, Xtandi, Zytiga|2 Comments
Read More

Hormone Therapy Will Only Last for A Short Time – A Myth Worthy of Being Debunked

One of the more common myths about hormone therapy (ADT) to treat prostate cancer is that its effectiveness will last only for one and a half to two years. For some men this might be true, but it is not a reality in today’s prostate cancer landscape. What makes this myth worse is that it [...]

By |2017-10-19T10:51:00-04:00July 20th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC|4 Comments
Read More

GTx Receives clearance for New Capesaris Trials

GTx Inc. announced that FDA regulators will allow it to restart the clinical trials of its investigational prostate cancer drug Capesaris for men with castrate resistant advanced prostate cancer. They anticipate that the trials of Capesaris will begin during the third quarter of 2012. The trial is designed to evaluate Capesaris as a secondary treatment [...]

By |2012-05-08T20:17:57-04:00May 8th, 2012|2nd line hormone therapy, Advanced Prostate Cancer, Capesaris, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, Hormone Therapy, Uncategorized|1 Comment
Read More

Identifying A New Pathway Explaining Resistance to Prostate Cancer Treatment

We al are very familiar with the significant problem in the treatment of prostate cancer, even therapies that initially work stop working and our disease continues to progress. The inevitable onset of this resistance to treatment with antiandrogens (ADT) such as Lupron or Zoladex is not limited just to this class of drugs. We have [...]

By |2017-10-19T10:52:07-04:00August 18th, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|10 Comments
Read More
Go to Top